Aldeyra Therapeutics, Inc. [CNN]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: CNN
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. A market capitalization up to $300 million places ALDX in the micro-capitalization category. Q earnings, quarter ending Dec 30, 2025 Q 1y Change Total revenue n/a n/a Net income - 6.46M Earnings per share n/a Net profit margin n/a n/a Free cash flow - 5.30M Debt-to-equity ratio ALDX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight. Net Income increased 39.4% since last year and increased 0.0% since last quarter. EPS increased 39.97% since last year and increased 0.0% since last quarter. ALDX's competitors are included
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & KorsinskyGlobeNewswire
- ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & KorsinskyPR Newswire
- ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics (ALDX) had its "neutral" rating reaffirmed by HC Wainwright. They now have a $2.00 price target on the stock, down from $10.00.MarketBeat
- FDA issues CRL to Aldeyra's reproxalap drug application [Yahoo! Finance]Yahoo! Finance
ALDX
Earnings
- 11/5/25 - Beat
ALDX
Sec Filings
- 3/17/26 - Form 8-K
- 2/27/26 - Form S-8
- 2/27/26 - Form 10-K
- ALDX's page on the SEC website